PROGRAM

View Program Timetable

Quick Links

Keynote Speakers

Invited Speakers

Preliminary Program

Awards

Developing Countries

Keynote Speakers

Dr Barry Shulkin

Dr Val Lowe

Dr Susan E M Clarke

Dear colleagues,

It is with regret that I must announce that Professor Steve Larson will not be able to participate in our conference as a guest speaker. There will be due adjustments to the programme which still boasts a faculty of 3 other eminent overseas speakers and many local experts. In addition, with the breadth of topics covered by the submitted abstracts I anticipate a very educational and interesting annual meeting.

I look forward to seeing you in Adelaide.

With kind regards.

Ghee Chew
Convenor

Invited Speakers

Associate Professor Paul Roach, Royal North Shore Hospital, NSW, Australia

Dr Stephen Allwright, Dee Why Nuclear Medicine, NSW, Australia

Ms Heather Patterson, Westmead Hospital, NSW, Australia

Dr Robin Cassumbhoy, Peter MacCallum Cancer Centre, Victoria, Australia

Dr Bob Cooper, Dee Why Nuclear Medicine, NSW, Australia

Dr Nathan Better, Royal Melbourne Hospital, Victoria, Australia

Nat Lenzo, Western Australia

Associate Professor Monica Rossleigh MD,FRACP, Department of Nuclear Medicine, Prince of Wales and Sydney Children's Hospitals

Dr Steve Unger, Director of Nuclear Medicine (QEH and LMH)

Pioneer Lecturer

Dr Barry Chatterton, Royal Adelaide Hospital, SA, Australia

Lowenthal Lecturer

Mr Peter Collins, Royal Adelaide Hospital, SA, Australia

Conference Highlights

Dr Michael Kitchener, The Queen Elizabeth Hospital, SA, Australia

Preliminary Program

Thursday, 26 April 2007
07:30 – 17:00 Registration
Accreditation Board Meeting
ANZSNMT Committee Meeting
08:30 – 17:00 ANZSNM Committee Meeting

Friday, 27 April 2007
07:30 – 17:00 Registration
08:30 – 13:30 Pre - Meeting Symposium at National Wine Centre Sponsored by Genzyme
08:30 – 09:15 Session 1
09:15 – 10:00 Session 2: Dr Sue Clarke
10:00 – 10:45 Session 3: Mr Rob Parkyn
10:45 – 11:00 Morning Tea
11:00 – 11:45 Session 4: Prof Val Lowe
11:45 – 12:30 Session 5: Prof Val Lowe
12:30 – 13:30 Lunch and end of Pre-Meeting Symposium
12:30 Golf with Gordon

Saturday, 28 April 2007
07:30 – 19:00 Registration
08:00 – 08:30 Advanced Trainees / Supervisors Meeting
08:30 – 10:30 ANZSNMT Symposium Sponsored by Radpharm
08:30 – 10:30 ANZAPNM Clinical Skills Symposium Sponsored by Bristol-Myers Squibb
08:30 – 10:30 Physicists SIG Symposium
10:30 – 11:00 Morning Tea
11:00 – 12:30 ANZSNMT Symposium Sponsored by Radpharm
11:00 – 12:30 ANZAPNM Clinical Skills Symposium Sponsored by Bristol-Myers Squibb
11:00 – 12:30 Physicists SIG Symposium
12:30 – 13:30 Lunch
13:30 – 15:30 ANZSNMT Symposium Sponsored by Radpharm
13:30 – 15:00 ANZAPNM Clinical Skills Symposium Sponsored by Bristol-Myers Squibb
13:30 – 15:00 Nurses SIG
15:00 – 15:45 Radiopharmacists SIG
15:45 – 16:00 Afternoon Tea
16:00 – 17:00 ANZSNMT Symposium Sponsored by Radpharm
16:00 – 17:00 ANZAPNM AGM
16:00 – 17:00 Radiopharmacists SIG
17:00 – 17:30 ANZSNM Witness Seminar
17:30 – 18:30 Mentor's Meeting
18:30 – 20:00 Welcome Reception - Opening of Trade Displays, Adelaide Convention Centre

Sunday, 29 April 2007
07:30 – 17:30 Registration
08:25 – 08:30 Official Opening - Mr Peter Collins
08:30 – 09:00 ANZSNM Special Guest: Prof Martin Sandler
09:00 – 09:45 Plenary 1
09:45 – 10:30 Plenary 2: Dr Sue Clarke
10:30 – 11:00 Morning Tea
11:00 – 11:40 Lowenthal Lecture: Mr Peter Collins
11:40 – 17:30 Concurrent Sessions
11:40 – 12:30 Free Papers and the Malinckrodt Award
12:30 – 13:30 Lunch
13:30 – 15:45 Paediatric Nuclear Medicine: Prof Barry Shulkin, Dr Monica Rosleigh
13:30 – 15:45 Professional Skills for Technologists Sponsored by Bristol-Myers Squibb
15:45 – 16:00 Afternoon Tea
16:00 – 17:30 Free Papers
16:00 – 17:30 Professional Skills for Technologists Sponsored by Bristol-Myers Squibb
19:00 - late Nuc’s Pub Crawl

Monday, 30 April 2007
08:00 – 17:30 Registration
09:00 – 09:45 Plenary 1: Prof Val Lowe
09:45 – 10:30 Plenary 2: Prof Barry Shulkin
10:30 – 11:00 Morning Tea
11:00 – 12:30 Concurrent Sessions with the ANZAPNM Registrar Award and the ANSTO Award
12:30 – 13:30 Lunch and Poster Defence
13:30 – 14:30 ANZSNM AGM
14:30 – 15:15 Pioneer Lecture: A/Prof Barry Chatterton
15:15 – 15:45 Concurrent Sessions - Free Papers
15:45 – 16:00 Afternoon Tea
16:00 – 17:30 Concurrent Sessions - Free Papers
19:00 – 01:00 GE Healthcare Gala Dinner, Adelaide Convention Centre

Tuesday, 1 May 2007
08:00 – 14:00 Registration
09:00 – 09:45 Plenary 1
09:45 – 10:30 Plenary 2: Prof Val Lowe
10:30 – 11:00 Morning Tea
11:00 – 12:15 Concurrent Sessions - Free Papers
12:20 – 12:40 Meeting Highlights: Dr Michael Kitchener
12:40 – 13:00 Introduction to the 38^th ASM: Dr David Wong
13:00 – 14:00 Close of Meeting: Mr Peter Collins

Awards

Poster Prizes

ANSTO Nuclear Medicine Award

ANZAPNM Registrar Award

Mallingckrodt Award for Nuclear Medicine Technologist

Radpharm Award

Poster Prizes

Delegates are invited to present their scientific data in poster form and vie for three prizes. The 'Global Medical Solutions Poster Prize' will be awarded to the poster judged to be of the most outstanding scientific merit. There will also be a "Convenor's Choice" Poster Prize for the poster with the best images. The 'Radiology SA Rookie Poster Prize' will be awarded to the best poster submitted by a trainee in any discipline relevant to Nuclear Medicine - medical, technologist, physics or radiopharmacy.

ANSTO Nuclear Medicine Award

RULES 1. The Award will be made for significant innovation in research or clinical practise in the field of Nuclear Medicine. It will be presented as a paper at the Conference. It must also have been accepted for oral or poster presentation at an international medical speciality meeting, or for publication in an international peer reviewed journal. The objective of the award is to highlight the high calibre of Australian Nuclear Medicine and ANSTO’s role in supporting it to a diverse an audience as possible – particularly the Nuclear Medicine referral base.

2. Entrants for the Award may be from any discipline within the field of Nuclear Medicine. The entrant must be a financial member of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM) of at least six months standing.

3. The Award is not open to employees of ANSTO, or for work or research carried out whilst an employee of ANSTO.

4. The material shall be presented as an oral paper at the Annual Meeting of the ANZSNM.

5. Candidates must provide a statement countersigned by his or her department head indicating the extent of assistance received during the course of the work. This statement plus four copies of the full manuscript shall be in the hands of the Scientific Programme Organiser at least four weeks prior to the Conference to enable short-listing and preliminary review of the work. All candidates will be notified of the outcome of this process at least one week before the conference..

6. The recipient of the Award must undertake to submit the written paper to the Editor of the ANZSNM Journal for publication within six months of receiving the Award. The manuscripts of non-winning entrants will be destroyed.

7. Within six months of the completion of the approved travel, the winner must make a technical report of 1500-2000 words to the Editor of the ANZSNM Journal for publication.

JUDGING
Papers submitted for the Award shall be judged by a panel of one Senior Researcher and one physician nominated by the Society and a representative of ANSTO. The judges must not be drawn from the same department as any candidate. The panel reserves the right not to make an award if it is deemed the standard is not sufficiently high. A simple majority vote of the panel (2) will govern all decisions. The panel shall meet prior to the first presentation to ensure that the judging criteria are understood.

The assessment for the Award will be on the basis of the following:
(a) Significance and merit of the data or procedure = 40%
(b) Scientific method of investigation or development = 30%
(c) Originality = 20%
(d) Presentation skills = 10%

THE AWARD
The Award will be for $3000 for documented expenses incurred to attend an international nuclear medicine meeting, eg. the Society of Nuclear Medicine or the European Association of Nuclear Medicine.

The successful applicant must provide ANSTO with his or her travel itinerary within six months of winning the Award.

ANZAPNM Registrar Award

GUIDELINES

The Award shall be known as The ANZAPNM Reigstrar Award. The Award is open to advanced trainees in nuclear medicine or to full-time research registrars in nuclear medicine, as part of a training program approved by the Joint Specialist Advisory Committee of the Royal Australasian College of Physicians (RACP) and the Royal Australian and New Zealand College of Radiologists (RANZCR). Recently qualified trainees may enter, provided that the work for the presentation was carried out during the period of training and is presented at the first Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM) after completion of training. Entries are limited to one per candidate. Entrants must be financial members of the ANZSNM at the time of presentation.

The Award is for work that provides new and significant data of clinical and Scientific merit and involves the use of nuclear medicine techniques.

The data will be presented as an oral paper at the Annual Scientific Meeting of the ANZSNM. Notification should be given with the submission of the abstract that the presenter wishes to be considered for the Award.

The candidate must provide a statement, countersigned by his or her department head, indicating the extent of assistance received during the course of the work. This statement plus four copies of the paper must be received by the ANZAPNM Secretariat no later than two weeks prior to the ANZSNM Scientific Meeting.

The recipient of the Award shall provide a summary of the paper to both the ANZSNM and to the ANZAPNM Secretariat, for publication in the ANZSNM Journal and the ANZAPNM Newsletter and/or website. Successful candidates wishing to submit their work to a peer-reviewed medical journal may be permitted to do so after consulting with the ANZAPNM President.

Papers submitted for the Award shall be judged by a panel of two physicians and one scientist, nominated by the ANZAPNM. Each member of the juding panel shall declare any conflict of interest, and shall not judge any paper submitted by a candidate from his/her department. The Award will be made at the discretion of the judges.

The weightings for the Award will be as follows:
(a) Significance and merit of the data - 40%
(b) Scientific method of the investigation - 30%
(c) Oral presentation skills - 20%
(d) Originality - 10%

The Award will be for travel up to A$3,000 to enable attendance at an approved nuclear medicine meeting. All details and bookings for the trip shall be finalised by 31 March of the year following presentation of the Award.

The judging panel reserves the right not to make an Award in any year.

The Award is administered by the ANZAPNM. All correspondence relating to the Award should be made to the ANZAPNM Secretariat, P O Box 73, Balmain NSW 2041 Australia.
(Published ANZ Nuclear Medicine June 2003)

Mallinckrodt Award for Nuclear Medicine Technologist

INTRODUCTION
The Mallinckrodt Award will be held in conjunction with the Annual Scientific Meeting (ASM) of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM). Its aim is to foster the spirit of innovation and progress in nuclear medicine.

The Award will be provided for an oral scientific or technical paper presented by an accredited nuclear medicine technologist.

DEFINITION FOR THE PURPOSE OF THIS AWARD
(a) Technologist: A financial member of the ANZSNM who is employed as an accredited technologist in the field of nuclear medicine or who has been granted interim accreditation and who has been a financial member of the society for at least six months.

(b) Scientific or technical paper: A paper constructed in the following format. Objectives, Materials/Methods, Results, Discussion and Conclusions

ENTRIES FOR THE AWARD

This Award will be made on investigational or other work presented orally at the ASM by the entrant.

Entries will be considered on their value in improving knowledge in any aspect of nuclear medicine. While the study need not be totally original, considerable attention will be paid to the basic idea, to the individual effort and to the lack of dependence on non-technical aspects such as scan interpretation or clinical assessment. The fundamental requirements of any scientific paper, such as clarity of description of the studied problem in the context of published data, critical evaluation of results, utilisation of statistical or other relevant methodologies, as well as the presentation itself, will be taken into account. Acknowledgment of people or agencies that have contributed substantially to the work must the included.

A candidate for the Award must submit an abstract for the ASM as with any other paper. Submission of abstracts must be in accordance with the requirements of the ASM.

All papers submitted for the award will be considered on their merits as to eligibly and final acceptance.

An accredited technologist entering for the Award shall provide a personally signed statement countersigned by the department head, indicating the extent of assistance given by others so that the judges can make an assessment of the proportion of the work done by the author(s) of the paper. This statement, plus an electronic copy and one hard copy of the full manuscript, shall be in the hands of the Professional Conference Organiser (PCO) at least three weeks prior to the beginning of the Conference.

The audience will be informed that the paper is an entry for the Award.

The recipient(s) of the Award must undertake to submit a copy of the manuscript to the Editor of the Society's Journal for publication within two months of winning the Award. All manuscripts of non-winning entrants submitted to the PCO will be destroyed.

MANUSCRIPT SUBMISSION FORMAT: Submitted on disc or by e-mail in Microsoft word. Forward one complete hardcopy. Each A4 page should be double spaced with font size of at least 10 points and paragraph indentation of at least 5 spaces.

Components of each manuscript must be submitted in the following order:
1. Title Page
2. Abstract
3. Text
4. Acknowledgments
5. References
6. Tables & Figure legends Pages should be number consecutively

FINANCIAL SUPPORT

If a candidate for the Award requires financial support to attend the ASM in order to present a paper, application should first be made to the employer. If this is unsuccessful, and the entrant wishes to seek support from the Society, application should be made to the local branch of the Society at least two months prior to the ASM.

Applications will be considered by each branch and a decision made on which author or authors it wishes to recommend that financial support be given. Such a decision will usually be based upon a presentation of the paper at a local branch meeting. The decision should then be forwarded to the Secretary not less than one month prior to the ASM.

The Executive of the Society will decide on the amount of money which the Society could provide and will advise the candidate through the Society. (The local branch is free to support a candidate with additional assistance.)

JUDGING
The judging panel shall consist of three society members drawn, where practicable, from the Accreditation Board of the Society. One should be the President of the ANZSNM or their nominee, who shall act as Chairman. One of the two remaining judges shall be a nuclear medicine technologist for whom no conflict of interest can be identified. A judge must not belong to the same department as a candidate.

The criteria upon which judgement will rely shall include the following (percentages are maxima):
(a) The value of the paper as a contribution to nuclear medicine technology - 25%
(b) The extent of direct assistance the author(s) receive from supervisors or other individuals
(c) The content of the paper (accuracy, logic, statistical consideration, originality, etc) - 50%
(d) The technique of presentation (clarity, expression, quality and use of slides, timing, handling of questions, etc) - 25%

The judges will have discretion as to whether an Award will be made. The successful candidate will receive a suitably inscribed trophy.

AWARD

The Award will consist of one return economy class airline ticket for the purpose of attendance at a major international scientific meeting such as the Annual Scientific Meeting of the Society of Nuclear Medicine or the European Association of Nuclear Medicine. In the case of multiple author entries, the Award will be shared.

A submission must be made to the Secretary of the ANZSNM outlining the proposed use of the Award ticket.

Following the completion of the approved travel, the winner(s) must make a technical report of 1500-2000 words to the Secretary for publication in the Society's Journal. This should be completed within six months of the travel.

Radpharm Award

RADPHARM Case Presentation Award Rules 1999
(Reviewed March 1999)

1. The RADPHARM Technologist Case Presentation Award, hereafter termed the Award, will be held in conjunction with the Annual Scientific Meeting (ASM) of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM), hereafter termed the Society.

2. Entries to the Award will be Nuclear Technologists employed within the field of Nuclear Medicine. Such entries will have been financial members of the Society for at least 6 months. Students undertaking an approved course of studying Nuclear Medicine are also eligible to enter.

3. The Award will be made for an Oral Case Presentation of a single (One ( 1)) patient's study(s) performed within Nuclear Medicine workplace.

4. The Award comprises two (2) parts. An initial Sponsorship (part 1 ) will be made to the winning entrant in the Home State. The Award (Part 2) will be made at the Technologist Symposium of the ASM.

Previous State Winners may submit and present further case studies, however, they will be ineligible to become the State Winning Entrant for a period of two years.

5. Entrants to Part I and Part 2 of the Award must present their case study in the same year, the case unchanged in the intervening period.

6. PART l - Sponsorship
6.1 Entries for the Award are to present an oral case study in their Home State or in New Zealand (NZ).

The Home State/NZ shall be the region in which:
a) the entrant is employed/studying in the field of Nuclear Medicine and,
b) where the case study was obtained.

6.2 The Home States in Australia shall deemed one of the following:
a) NSW (including ACT)
b) QLD
c) SA(including NT)
d) TAS
e) VIC
f) WA

6.3 Entrants to the Award are to present to the State/NZ Branch representative of the ANZSNM Technologist Group (ANZSNMT) a signed statement, countersigned by the department head indicating the extent of assistance received during the course of the case study work. In the case of a video presentation this statement should also confirm that the presentation was performed in accordance with the Rules and that the video has not been edited.

6.4 The winner of the State/NZ sponsoring will be required to provide this statement to the Hon. Secretary ANZSNMT on submission of the abstract to Part 2 of the Award.

6.5 Entrants to the Award (Part l and 2}, are to present their case study in a maximum of ten (10) minutes. The total presentation time will be divided as:
a) oral case presentation -7 minutes (maximum)
b) question time -3 minutes (maximum)

6.6 The State Branch/NZ Branch representative of the ANZSNMT will organise a venue and time for the presentation of case by entries to the Award, in the February immediately prior to the ASM of the Society each year. Entrants to the Award who are normally located remotely from the presentation venue may submit a video presentation, performed before an audience of professional healthcare colleagues, to be viewed by the audience and judges at the presentation meeting. The current entrant will be available via telephone link to answer questions from the presentation meeting.

6.7 Judges for the State/NZ sponsorships shall determine the winning case presentation. The home State/NZ entrant awarded the sponsorship shall be termed a National or NZ finalist.

6.8 The State/NZ sponsorships shall be Judged by panel of three (3) Nuclear Medicine Technologists. The panel will be nominated by the State Branch representative of the ANZSNMT. The panel must include the nominated State representative of the ANZSNMT. All panel members are to be full financial members of the Society, and eligible for accreditation. Where possible the judging panel should not be drawn from the same workplace/department as any entry to the award.

6.9 If there is only one case presentation within a State/NZ, the case study must be presented to a panel of three (3) Nuclear Medicine Technologists at a presentation night or Branch meeting. The panel of judges must judge whether the presentation is worthy and hence eligible for the Sponsorship. If judged to be unworthy, there will be no winner from that Home State or NZ.

6.10 The National and NZ finalist will be sponsored by RADPHARM to A$500 towards attending the Technologist Symposium of the ASM, to present their winning case study. Winners of Part 1 Sponsorships, are the only entrant to Part 2 of the Award.

7. PART 2 - The Award
7.1 National and NZ finalists must submit an abstract of their winning case presentation for the Technologist Symposium as with any paper. Submission of abstract must be in accordance with the requirements of the ASM.

7.2 The audience wi]l be informed that the presentation is an entry for the RADPHARM Technologist Case Presentation Award

7.3 The Award will be judged by a panel of seven (7) Nuclear Medicine Technologist representatives, each nominated by their State/NZ Branch representative of the ANZSNMT. The judging panel must not be drawn from the same department/workplace as entry to the Award.

8. The Sponsorship and the Award will be decided on the following criteria with value specified,
a) - Originality
b) - Presentation
c) - Content (Correlative Investigations may be used.)
d) - Interest/Value of paper to Nuclear Medicine
e) - Contribution of Nuclear Medicine to patient management.

9. The RADPHARM Technologist Case Presentation Award will be presented at the conclusion of the Conference.

10. The recipient of the Award should provide to the ANZSNMT Honorary Secretary, an appropriate summary of the case study presentation for publication in the ANZSNMT Newsletter.

Dr Barry Shulkin

Dr Shulkin is chief of nuclear medicine at St. Jude Children's Research Hospital, Memphis, TN, USA. He served on faculty of the University of Michigan for 18 years and was recently chairman of the pediatric council of the Society of Nuclear Medicine. His principal interests are functional imaging of endocrine and pediatric tumors.

Dr Steven Larson

Steven M. Larson, M.D. is Attending Physician, Department of Radiology and Member, Memorial Sloan Kettering Cancer Center, and Professor, Department of Radiology, Weill Cornell University Medical Center. Dr Larson is Chief of Nuclear Medicine Service, Vice Chairman for Radiology Research, and Director, the Laurent and Alberta Gerschel Positron Emission Tomography Center, Department of Radiology Memorial Hospital.

Dr Larson is also Laboratory Head, Molecular Pharmacology and Chemistry Program, and Co-Director of the Ludwig Trust Center for Immunotherapy of Sloan Kettering Institute (SKI). Dr Larson's research focus is molecular imaging and targeted therapy, particularly PET and radioantibody targeted therapy in oncology. He is the author and co-author of more than 500 scholarly publications and has been awarded numerous honors in nuclear medicine, including the Hevesy Awards of both the European and the US Society of Nuclear Medicine; Radiology Researcher of the year (2004) and the Pendergrass Awards of the Radiologic Society of North America. He is a member of the Institute of Medicine of the National Academy of Sciences, USA.

Dr Val J. Lowe

Dr Lowe is a leader in the advancement of clinical PET and PET/CT. Dr Lowe has authored seminal works that have led to the approval and use of PET in clinical oncology in multiple disease specific indications. He is an internationally known teacher and lecturer on the use of PET in clinical practice. He is faculty member at Mayo Clinic in Rochester, Minnesota and is the director of the Mayo Clinic PET Facility and Molecular Imaging Research Center.

Dr Susan E M Clarke

Sue Clarke has been a consultant for over 20 years with a specialty interest in Thyroid disease. She heads a busy Thyroid service and is clinical lead for the nuclear medicine imaging service. She is an ex president of the BNMS, was chair of the EANM Therapy committee and is chair of the Professional Standards Committee of the BNMS.

Associate Professor Paul Roach

Associate Professor Paul Roach is the Head of the Department of Nuclear Medicine at Sydney's Royal North Shore Hospital. In collaboration with the hospital's Department of Respiratory Medicine, his team has developed new techniques in VQ SPECT imaging. These include the use of fusion imaging, new methodology to generate planar images from SPECT data and novel quantitative techniques to assess pathophysiology in pulmonary embolism and other respiratory conditions.

Dr Stephen Allwright

Dr Stephen Allwright is a Nuclear Medicine Physician, trained in paediatric nuclear medicine at Children's Hospital Los Angeles and currently in private practice at the Mater Hospital in Sydney and at Dee Why Nuclear Medicine. He developed an interest in sports medicine and musculoskeletal bone scanning. He is the co-author of Atlas of Nuclear Imaging in Sports Medicine with Dr Bob Cooper and Dr Jock Anderson.

Ms Heather Patterson

Heather Patterson, Westmead Hospital, Sydney has been involved with national and international training in the practical applications of nuclear medicine technology for over 20 years. Recent achievements include the development and coordination of the Distance Assisted Training program for NM Technologists under direction of the International Atomic Energy Agency, Vienna.

Dr Robin Cassumbhoy

Dr Robin Cassumbhoy is a staff radiologist at Peter MacCallum Cancer Centre in Melbourne, where she completed a fellowship in Cross-Sectional Imaging in 2002. Her interests include head and neck imaging, medical graphics and illustration, and teaching of cross-sectional CT anatomy at undergraduate and postgraduate levels with a unique approach.

Dr Bob Cooper

Bob Cooper is a Nuclear Medicine physician at Royal North Shore Hospital in Sydney, in the Mater Misericordiae Hospital and at Dee Why Nuclear Medicine. Bob has had a long interest in musculoskeletal Nuclear Medicine and enjoys educating in this field.

Dr Nathan Better

Dr Nathan Better is Deputy Director of Nuclear Medicine and a Cardiologist at the Royal Melbourne Hospital. After training in Melbourne, he completed Nuclear Medicine and Cardiology training in Boston, USA. He works in general nuclear medicine and clinical cardiology and he has a special interest in Nuclear Cardiology. His major research interest is in acute chest pain imaging and in risk stratification with myocardial perfusion imaging.

Associate Professor Monica Rossleigh

Associate Professor Rossleigh is Head of Nuclear Medicine at The Prince of Wales and Sydney Children's Hospitals and Associate Professor of Medicine at the University of New South Wales. Her research interests have been in the Nuclear Medicine Investigation of Paediatric Renal Disorders and she was awarded a doctorate by the University of New South Wales for this research work.

Associate Professor Rossleigh undertook Nuclear Medicine training at Sydney Hospital, Sir Charles Gairdner Hospital in Perth and Royal Prince Alfred Hospital in Sydney as well as at The Memorial Sloan-Kettering Cancer Center in New York. She has previously worked as a Nuclear Medicine Consultant at Royal Brisbane Hospital and at Royal Prince Alfred Hospital and have co-authored 81 scientific papers and written 6 book chapters.

Developing Countries

EUROPE
Albania
Armenia
Azerbaijan
Bosnia and Herzegovina
Croatia
Georgia
Gibraltar
Macedonia (former Yugoslav Republic)
Malta
Moldova
Slovenia
Turkey
Yugoslavia, Federal Republic

AFRICA
North of Sahara
Algeria
Egypt
Libya
Morocco
Tunisia

South of Sahara
Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Central African Republic
Chad
Comoros
Congo, Republic
Congo, Democratic Republic
Cote d'Ivoire
Djibouti
Equatorial Guinea
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mauritius
Mayotte
Mozambique
Namibia
Niger
Nigeria
Rwanda
St. Helena
Sao Tome & Principe
Senegal
Seychelles
Sierra Leone
Somalia
South Africa
Sudan
Swaziland
Tanzania
Togo
Uganda
Zambia
Zimbabwe

North & Central AMERICA
Anguilla
Antigua & Barbuda
Aruba
Barbados
Belize
Costa Rica
Cuba
Dominica
Dominican Republic
El Salvador
Grenada
Guatemala
Haiti
Honduras
Jamaica
Mexico
Montserrat
Netherlands Antilles
Nicaragua
Panama
St. Kitts and Nevis
St. Lucia
St. Vincent & Grenadines
Trinidad and Tobago
Turks & Caicos Island
Virgin Islands (UK)

SOUTH AMERICA
Argentina
Bolivia
Brazil
Chile
Colombia
Ecuador
Guyana
Paraguay
Peru
Suriname
Uruguay
Venezuela

ASIA
Afghanistan
Bangladesh
Bhutan
Burma
Cambodia
China, (excl. H.K.)
East Timor
India
Indonesia
Kazakhstan
Korea, Democratic Republic
Korea, Republic
Kyrgyz Republic
Laos
Macao
Malaysia
Maldives
Mongolia
Nepal
Pakistan
Philippines
Sri Lanka
Tajikistan
Thailand
Turkmenistan
Uzbekistan
Vietnam

MIDDLE EAST
Bahrain
Iran
Iraq
Jordan
Lebanon
Oman

TERRITORIES ADMINISTERED BY THE PALESTINIAN AUTHORITY
Saudi Arabia
Syria
Yemen

PACIFIC
Cook Islands
Micronesia, Federated States
Fiji
Kiribati
Marshall Islands
Nauru
New Caledonia
Niue
Northern Marianas
Palau Islands
Papua New Guinea
French Polynesia
Samoa
Solomon Island
Tokelau
Tonga
Tuvalu
Vanuatu
Wallis & Futuna